Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment

PATRIZIA MONDELLO, VINCENZO PITINI, CARMELA ARRIGO, ENRICO DERENZINI and MICHAEL MIAN
Anticancer Research September 2014, 34 (9) 5121-5125;
PATRIZIA MONDELLO
1Department of Human Pathology, University of Messina, Messina, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: patriziamondello@hotmail.it
VINCENZO PITINI
1Department of Human Pathology, University of Messina, Messina, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CARMELA ARRIGO
1Department of Human Pathology, University of Messina, Messina, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ENRICO DERENZINI
2L. and A. Seràgnoli Institute of Hematology, S. Orsola-Malpighi Hospital, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL MIAN
3Department of Hematology, Hospital S. Maurizio, Bolzano/Bozen, Italy
4Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Treatment algorithm.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Kaplan–Meier analysis of disease-free survival (DFS) (A; p=0.001), Progression-free survival (PFS) (B; p=0.007) and Overall survival (OS) (C; p=0.507) according to Zevalin ® consolidation.

Tables

  • Figures
  • Table I.
  • Table II.
  • Table III.
PreviousNext
Back to top

In this issue

Anticancer Research: 34 (9)
Anticancer Research
Vol. 34, Issue 9
September 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
15 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment
PATRIZIA MONDELLO, VINCENZO PITINI, CARMELA ARRIGO, ENRICO DERENZINI, MICHAEL MIAN
Anticancer Research Sep 2014, 34 (9) 5121-5125;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment
PATRIZIA MONDELLO, VINCENZO PITINI, CARMELA ARRIGO, ENRICO DERENZINI, MICHAEL MIAN
Anticancer Research Sep 2014, 34 (9) 5121-5125;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis
  • Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy
  • Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients With Palbociclib
Show more Clinical Studies

Similar Articles

Keywords

  • 90Y-Ibritumomab tiuxetan
  • Salvage therapy
  • DLBCL
  • lymphoma
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire